Securities and Exchange Commission may increase its investigations of U.S. Sanctions violations by companies

Late last year, the Securities and Exchange Commission (“SEC”) penalized a public company for violating U.S. economic sanctions. The violation cited the “books and records” and “internal controls” provisions of the Securities Exchange Act of 1934 (the “Exchange Act”). On September 26, 2019, the SEC issued an Order instituting...
Continue reading…

Securities & Exchange Commission investigates Robinhood for selling clients’ orders to high speed trading firms

Robinhood Markets Inc. is under investigation by the Securities & Exchange Commission for failing to disclose its practice of selling clients’ orders to high-speed trading firms, according to Bloomberg News, quoting sources. Prior reports of SEC filings supported the reports of high-frequency trading firms paying Robinhood 10 times as much as they pay to...
Continue reading…

SEC awards Wall Street analyst whistleblowers $2.5 million for unveiling accounting violations by Orthofix International

Two Wall street investment advisers that were analyzing the financial documents of a Texas medical device company Orthofix International, noticed some inconsistencies in those reports. They decided to look more closely, all based upon the publicly available submissions to the Securities & Exchange Commission, and they did some statistical modeling to help. The concluded...
Continue reading…

Boston based Alexion Pharmaceuticals pays $21.5 million to settle charges of foreign bribes in Turkey, Russia and Brazil to sell their drugs

Boston-based Alexion pharmaceutical company, agreed to pay $21.5 million to settle charges it violated the Foreign Corrupt Practices Act (FCPA). A settlement, announced by the Securities and Exchange Commission (SEC), alleges that the company’s foreign subsidiaries in Turkey and Russia paid government officials to promote their drugs and that their Brazilian and Columbian subsidiaries...
Continue reading…

Alexion Pharmaceuticals agrees to pay $21 million to settle SECcharges of foreign bribes for Soliris to Turkish and Russian officials

The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA). According to the SEC’s order,...
Continue reading…